PharmaCorp Rx Inc.
PCRX.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -714.10K | -435.40K | -150.20K | -158.90K | -75.20K |
| Total Depreciation and Amortization | 55.60K | 16.40K | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 537.50K | 3.00K | -- | -- | -- |
| Change in Net Operating Assets | -350.40K | 301.00K | 9.80K | -54.20K | 14.50K |
| Cash from Operations | -471.40K | -115.00K | -140.40K | -213.10K | -60.70K |
| Capital Expenditure | 0.00 | -5.00K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.53M | 58.60K | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.53M | 53.60K | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -40.70K | -15.30K | -- | -- | -- |
| Issuance of Common Stock | 7.64M | 19.86M | -- | 0.00 | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5.57M | 14.50M | -- | 0.00 | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.57M | 14.44M | -140.40K | -213.10K | -60.70K |